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ABSTRACT – 
 
Dysregulation of the oncogene H-Ras pathway is widely found in human 
superficial bladder cancer, while a Rb mutation co-exists with H-Ras mutation in the 
majority of invasive tumors. Preliminary data on mice with bladder-specific H-Ras 
activation and other previous reports on in vitro cell line assays have indicated that 
cellular senescence, a defense response that leads to irreversible cell cycle arrest and 
provides a barrier for tumor progression, can be induced by H-Ras activation. Extra 
mutations in tumor suppressors such as Rb could contribute to the breaking of 
senescence and tumor progression.  
Investigation into senescence began with immunohistochemistry on human 
bladder samples for phosphoERK and Rb, which found that phosphoERK was more 
commonly involved with the initiation of bladder cancer while Rb was more involved with 
its progression. With this data, a double transgenic mouse model was created with 
constitutively activated H-Ras and knocked out Rb, which was hypothesized to break 
the senescence response. The mice were bred and euthanized, with their bladders’ 
senescent activity bladders analyzed using beta-galactosidase and p15. Interestingly, 
we found a significant correlation between the H&E/beta-galactosidase of the double 
transgenic and H-Ras mice as compared to the normal mice, showing that an extra 
mutation was not sufficient to break senescence at the age of 6-months. Additionally, 
p15 was not found to not be an effective senescent indicator, with no patterns seen 
between the three genotypes of mice. Further analysis includes assessment of our 1-
year-old mice and investigation towards other tumor suppressors that may drive tumor 
progression.   
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INTRODUCTION –  
 
Bladder Cancer Background - Bladder cancer stands as the 4th most common 
cancer in males and the 8th most common in females.9 Furthermore, bladder cancer is 
known as the most expensive type of cancer to treat due to its high recurrence rate and 
the costly methods of its treatment.9 Extensive efforts are being put toward reducing the 
treatment costs and recurrence of this disease through the creation of a transgenic 
mouse model that ideally mimics human cancer conditions. This novel medium allows 
scientists to test and ensure the safety of anti-cancer therapies on mice, leading to their 
integration into human bladder cancer treatment. Since body structure, development, 
and gene regulation are very similar between mice and humans, using mice to examine 
this disease will provide a relatively accurate model with results that are applicable to 
human cancer.  
 Cancer is a disease that is often modeled in vitro, through the creation of cell 
lines, or in vivo, through the creation of animal models. Mouse models are often 
preferred in order to provide the most accurate model of bladder cancer development. 
To better understand and treat human bladder cancer, animal models are vital, 
especially those that include genetic changes identified in human tumors. Yet, there has 
been a lack of these types of models that are representative of the human disease in 
the field of bladder cancer research. The lab’s objective has been to create a relevant 
mouse model that mimics the human form of bladder cancer in both phenotype and 
disease progression.  
Two of the most common defense responses studied in cancer are apoptosis 
and senescence. While apoptosis involves programmed cell death, senescence leads to 
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cell cycle arrest and the cell entering a state of irreversible quiescence.4 Senescence is 
a key cellular defense in bladder cancer that can halt the formation and spread of 
tumors.4 Experimentally, senescence is often activated in response to an oncogenic 
signal, such as H-Ras.3 Considerable cell line evidence exists to support the concept of 
oncogene induced senescence.3 The Rb and p53 pathways may be key regulators of 
the senescence response.1  A recent study in fibroblast cell lines suggested Rb as the 
key member of the RB family that has independent and non-overlapping functions that 
contribute to senescence in the context of Ras activation.5 This information leads to the 
hypothesis that cellular senescence is the reason why a low rate of cellular proliferation 
and lack of a more aggressive tumor is seen in the H-Ras transgenic mouse model of 
bladder cancer. Additionally, this information advances the notion that the knockout of 
the tumor suppressor Rb will promote further tumor progression by releasing the 
senescence barrier. 
Ras Pathway - Human bladder cancer is classified in two different forms: 
superficial, the tumor is confined to the epithelium; and invasive, the tumor invades 
through the epithelium and in to the underlying muscular layers (see Figure 1). Both 
pathways have unique mutation events that characterize their representative cancer 
progression pathways. Ultimately, each incidence of bladder cancer can be labeled by 
increasing severity, from Ta to T1 to T2 to T3 to T4 (see Figure 2). These stages of 
bladder cancer represent the tumor progression from the epithelium through the 
basement membrane and into the muscle layer. The superficial form is far more 
common, but the invasive form is more dangerous as it causes more deaths.6  
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The lab’s efforts have focused on the specific pathway from low-grade superficial 
tumor to high-grade invasive tumor with the creation of a transgenic mouse model. 70-
80% of superficial tumors are caused by dysregulation of the H-Ras pathway, but 
additional mutations such as p53 and Rb are necessary for the formation of the invasive 
cancer.6 The model started with a mutated, activated H-Ras +/- mouse strain driven by 
Uroplakin II (UPII), a bladder-specific promoter, created by Dr. Wu at New York 
University.6 The tumor that the mouse develops has a long latency, grows slowly, and 
does not progress to the invasive form. This preliminary information combined with lab 
mice staining shows that no matter how high the H-Ras gene dosage in the mouse 
bladder, the tumor will not become invasive and the rate of cellular proliferation remains 
low (see Figure 3).  
These hematoxylin and eosin (H&E) stains show the epithelial (purple) vs. 
muscular (pink) layers in the mouse tissue, highlighting the difference between the 
normal epithelium (around 3 cell layers) and the Ras +/- mice which show hyperplasia 
(can exceed 10 cell layers thick). In addition, the urothelium in H-Ras mutated mice 
contains more senescent cells when compared to the bladder of wild-type mice (see 
Figure 4). Beta-galactosidase staining was completed on both tissue samples and the 
senescent cells are indicated through the formation of a blue stain. Therefore, the Ras 
signaling pathway in the bladder is associated with senescence, but this mutation in the 
pathway is not sufficient to induce invasive tumor progression.  
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METHODS –  
 
Human Bladder Samples – Human bladder samples were obtained from the  
OSU tissue bank and were approved for use by the Ohio State Institutional Review 
Board.  
Immunohistochemistry for Rb and phosphoERK - Human bladder sections 
were sliced to 4µm thick from paraffin blocks onto slides. After deparaffinization and 
rehydration, the tissue sections were blocked with hydrogen peroxide for 20 minutes, 
steamed in 10mM sodium citrate buffer (pH 6.0) for 12 minutes, and cooled to RT. The 
slides were blocked for 1 hour with goat serum and stained against phosphoERK (Cell 
Signaling, 1:100) and Rb (Cell Signaling, 1:100) overnight. Then, the slides were 
incubated with a secondary antibody (phoshpoERK – anti-rabbit 1:500, Rb - anti-mouse 
1:500) and a strep label (1:250 peroxidase) for 1 hour each at RT. Lastly, the slides 
were incubated for 3 minutes in DAB solution, counter stained with hematoxylin, 
dehydrated, and mounted. For phosphoERK, the slides were rated “intensified” as 
based on comparison to WT (wild type, normal) human tissue samples. For Rb, the 
slides were rated “inactivated” if staining was seen completely negative due to the loss 
of the Rb gene entirely or if all of the Rb had been phosphorylated to become its 
inactivated version.  
Mouse Model - Over the past two years, a double transgenic mouse was 
created that carries the activating mutation in H-Ras and knockout of the tumor 
suppressor Rb specifically in the urothelium, in order to determine whether Rb 
contributes to the senescence response and if the knockout of Rb changes the 
phenotype of the tumor (see Figure 5). An H-Ras mutated mouse driven by UPII (UPII-
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H-Ras) was kindly provided by Dr. Wu’s lab from New York University, and was then 
crossed with an Rbf/f mouse in order to knockout Rb in only the bladder epithelium.6 
Then, a Cre recombinase mouse with UPII (UPII-Cre), which was also kindly provided 
by Dr. Wu’s lab, was crossed also with an Rbf/f mouse.6 The transgenic UPII-Cre; RbF/+ 
mouse was crossed with the UPII-H-Ras; Rbf/+ mouse in order to create a transgenic 
with the ultimate genotype of UPII-Cre; Rbf/f; UPII-H-Ras. The wild type, UPII-H-Ras, 
and UPII-Cre; Rbf/f control groups were also maintained in order to have an 
experimental baseline. The mouse colonies were managed until the ages of 6 months 
and one year (the remaining mice will begin to reach one year of age in June). At these 
time points, the mice were euthanized and their bladders were harvested and preserved 
in paraffin as well as for fresh frozen samples.  
Immunohistochemistry for p15 – Mouse bladder sections were sliced to 4µm 
thick from paraffin blocks onto slides. After deparaffinization/rehydration, the tissue 
sections were blocked with hydrogen peroxide, steamed in 10mM sodium citrate buffer 
(pH 6.0), and treated with protein-blocking solution for 10 minutes each (EXPOSE 
Rabbit Specific HRP/DAB detection IHC Kit, Abcam). The slides were stained against 
p15INK4b (antibodies-online, 1:200) for 1.5 hours and then were incubated with Rabbit 
HRP secondary antibody for 15 minutes at RT. Lastly, the slides were incubated for 3 
minutes in DAB solution, counter stained with hematoxylin, dehydrated, and mounted. 
The slides were viewed under 10x magnification and were rated based on brown color 
intensity in the epithelial cytoplasm from + being the least intense to +++ being the most 
intense.  
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 Beta-galactosidase staining – Mouse bladder sections were sliced to 10mm 
thick sections from frozen and plated on slides. Then, the slides were stained with fixing 
solution for 15 minutes, washed twice in PBS, then covered with staining solution mix 
and incubated at 37°C overnight according to manufacturer’s instructions (Calbiochem). 
The slides were viewed under 10x magnification and significant progression towards 
senescence was defined as more than 20% of the slide’s epithelial layer staining blue 
(occurring in the nucleus of the epithelial cells). All of the slides were rated using + to 
indicate 0-20% epithelial staining (normal), ++ to indicate 20-60% epithelial staining 
(significant senescent activity), and +++ to indicate 60-100% epithelial staining 
(substantial senescent activity).  
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RESULTS –  
  
 PhosphoERK Analysis – In order to provide future directions for the mouse 
model, the lab worked to extend the H-Ras mutation information by focusing on 
phosphoERK, a downstream component of the Ras signaling pathway. Ras is involved 
in the normal maintenance of the bladder through its control over the G1 to S 
checkpoint in the cell cycle (see Figure 6).10 To test the role of Ras and the defense 
mechanisms involved in the body’s protection against mutations that cause these 
tumors, phosphoERK and Rb were stained for in human bladder tumor tissue samples. 
ERK is a mitogen-activated protein kinase and phosphoERK is ERK’s activated 
(phosphorylated) form. Rb is a key tumor suppressor involved in the last step of this cell 
cycle checkpoint pathway that releases E2F1-3 upon phosphorylation, which leads to 
the activation of the S phase.10  
H&E staining of both of these downstream components of the Ras pathway has 
demonstrated that the Ras-MAPK pathway is activated in most human bladder tumors 
of different grades and stages (see Figure 7). PhosphoERK is more commonly activated 
in the early stages of bladder cancer (Ta through T2), while Rb is more commonly 
activated in the later stages of bladder cancer (T1 through T4). These results suggest 
that ERK plays a greater role in tumor initiation and Rb plays a greater role in tumor 
progression. As the lab’s objective has been to create a mouse model that mimics the 
progression of bladder cancer from superficial to invasive, these findings substantiate 
our focus towards the mutation of the tumor suppressor Rb in the mouse model.  
Additionally, H&E staining for phosphoERK was completed on WT (normal) and 
Ras mutated mice, both homozygous Ras +/+ and heterozygous Ras +/- (see Figure 8). 
 10 
Although significant hyperplasia was seen in the UPII-H-Ras mutated mice, the high 
Ras concentration was not sufficient to push the bladder towards an invasive tumor as 
seen by the intact muscle layer. This further backs ERK’s non-involvement in bladder 
cancer tumor progression. 
 Mouse Model – Bladders from the ultimate genotype (UPII-Cre; Rbf/f; UPII-H-
Ras) mice and the control group mice (wild type, UPII-H-Ras, and UPII-Cre; Rbf/f) were 
collected (see figure 9). Phenotypically, minor bulging was seen in the bladder area with 
general confusion (running in circles, flipping), possibly caused by the “leaky” nature of 
the mutated H-Ras gene. Hyperplasia is seen in the epithelium of both the UPII-H-Ras 
mouse and the double transgenic (UPII-Cre; UPII-H-Ras; Rb f/f), as compared to the 
WT mouse.  
Senescence Assay - A significant correlation was seen between the 
senescence in the Ras and double transgenic mice as compared to the WT mice, based 
on the beta-galactosidase staining (see figure 10 & 11). Intense blue coloration in both 
of these transgenic mice groups correlates to a significant amount of the senescence 
defense response being activated. The H&E stains of both animals also act to connect 
the Ras and double transgenic based on their similarities in hyperplasia as compared to 
the WT mice. An intact muscle layer on both mutated mice shows that they have only 
formed the low-grade superficial bladder cancer. However, the cytoplasmic p15 staining 
seen in the epithelium was across the board in intensity, with no considerable patterns 
seen between the different genotypes. With this in mind, p15 was found to be an 
ineffective senescence marker.  
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DISCUSSION AND FUTURE DIRECTIONS –  
 
Preliminary data has shown that the mutation of H-Ras was not sufficient to drive 
bladder cancer from superficial (hyperplasia) to invasive (tumor). Staining for phospho-
ERK, a downstream component of the Ras signaling pathway showed that it was mainly 
a player in the initiation, but not the progression of bladder cancer. 
Immunohistochemistry of human bladder tumor samples showed that Rb, another 
downstream player of the signaling pathway, was significant in the progression of tumor 
development. Thus, a double transgenic mouse model was created to mutate H-Ras 
and Rb, in order to accelerate tumor development.  
Upon thorough analysis of the H&E, p15, and beta-galactosidase stains of 
the 6-month old mutated mice, it has been initially seen that inactivation of the 
tumor suppressor Rb is not sufficient to accelerate the development of bladder 
cancer from superficial to invasive. Based on a comparison to WT mice, great 
similarities were found between the H-Ras and our ultimate H-Ras; Cre; Rbf/f mice.  The 
lab’s initial hypothesis was that an additional mutation in the Ras signaling pathway with 
tumor suppressor Rb would be significant enough to break the cell’s senescence 
defense response, but this was not seen in our 6-month mice. Therefore, another 
component in the biological signaling pathway must compensate for the loss of Rb.  
One explanation for these results could be that another tumor suppressor, p53, is 
able to compensate for the loss of Rb.8 Another possible explanation could be that other 
members of Rb’s pocket protein family, such as p130 or p107, compensate for Rb’s 
loss. A final explanation could be that a significant amount of time has not yet passed in 
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our 6-month mice in order to see the full transformation from superficial to invasive 
cancer and for specific biological modifications to occur.  
Future project expansion includes further senescence staining with p16, Dec1, 
and DcR2 markers on our current mice bladder tissue. These markers have been 
documented as being useful in measuring senescence in the bladder and these results 
will work to corroborate with the lab’s current results.2 At the age of one year (starting in 
June), the remainder of our mice will be euthanized in order to provide a further 
benchmark for tumor development. Beta-galactosidase staining and 
immunohistochemical staining will again be completed for p15, p16, Dec1, and DcR2.   
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FIGURES -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
          This figure represents the breakdown of bladder cancer into superficial (hyperplasia) and invasive 
(dysplasia) strands, highlighting some of the common biological pathways mutated in the progression of 
papillary to invasive tumors. The asterisks represent a mutated version of the original gene present in the 
correlating forms of bladder cancer.  
 
Figure 2 
          A visual representation of the bladder, including the various stages of bladder cancer progression 
and their invasion into the bladder muscle layer. 
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Figure 3 
          These H&E stains show the epithelial (purple) vs. muscular (pink) layers in the mouse tissue. Note the 
difference between the normal epithelium (around 3 cell layers) and the Ras +/- mice which show hyperplasia and 
near tumor progression (can exceed 10 cell layers thick). 
 
Figure 4 
 These beta-galactosidase stains indicate senescence levels through the appearance of a blue color in 
the nucleus of the cells. As seen here, the Ras +/- mouse has significantly more senescence than the WT 
mouse.  
Figure 5 
          This breeding scheme shows the strategy used to create our ultimate double transgenic mouse model 
with bolded genotype above. We used the UPII (uroplakin II, bladder epithelial specific protein) promoter to 
drive the mutated H-Ras (constitutively activated form) to induce cancer expression. Rb
f/f
 represents the floxed 
version of the normal tumor suppressor that can be knocked out by the expression of Cre inside their cells. A 
Cre-floxed system is powerful when used in animal models to knock out a gene, which is Rb in our mice.  
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Figure 6 
           A vital biological signaling pathway involved in normal maintenance of the bladder’s G1 to S checkpoint, 
highlighting the downstream roles of ERK (a mitogen-activated protein kinase) and Rb from Ras.  
 
Human Bladder Tumors 
Figure 7 
This chart shows immunohistochemical staining for phospho-ERK (phosphorylated ERK, activated form of 
ERK) and Rb of human bladder tissue during the different stages of bladder cancer development. For 
phosphoERK, the slides were rated “intensified” as based on comparison to WT (normal) human tissue samples. 
For Rb, the slides were rated “inactivated” if staining was seen completely negative due to the loss of the Rb gene 
entirely or if all of the Rb had been phosphorylated to become its inactivated version. This most importantly notes 
the role of Rb in tumor progression and the role of phospho-ERK in tumor initiation, indicated by the yellow 
shading.   
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 Mouse Colony Information 
 
Mice 
Euthanized at 
age of 6-
months 
Mice to be 
Euthanized at 
age of 1 year 
Double Transgenic 5 26 
Ras 6 29 
WT 5 22 
 
 
 
 
 
Figure 8 
          The first photos show the size of a WT mouse bladder (~0.5 cm) as well as immunohistochemical staining 
for phospho-ERK. Following those is phospho-ERK staining of a heterozygous Ras mouse displaying mild 
hyperplasia. The second row shows a homozygous Ras mouse bladder (~1.5 cm) with its H&E and phospho-ERK 
staining. Although extreme hyperplasia is seen in this homozygous mouse, the high Ras concentration is not 
sufficient to push the bladder towards an invasive tumor as seen by the intact muscle layer. 
 
Figure 9 
 This chart shows the number of mice we have bred and the controls we have used to evaluate our 
hypothesis. Double transgenic refers to the mice with the ultimate genotype of UPII-Cre; Rb
f/f
; UPII-H-Ras, 
while Ras refers to a genotype of UPII-H-Ras, and WT refers to a normal (non-mutated) mouse. The first 
group highlighted in green represent the mice already euthanized and analyzed, while the second column 
represents the group of mice we will sacrifice once they reach the age of 1 year old.  
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Figure 10 
These mouse bladder sections represent a sample of the 16 total mice euthanized and harvested at the 
age of 6-months old. All 3 columns represent sections from the same animal, while each row represents a different 
type of staining analysis. All sections were viewed under the microscope at a magnification of 10x.  
Row A represents the H&E stains of the 3 mice genotypes. With H&E staining, a lighter pink color 
represents the muscle layer of the bladder, while the darker purple layer represents the epithelial layer. The WT 
mouse represents a normal epithelium, around 3 layers thick. The Ras and double transgenic mice represent a 
bladder displaying hyperplasia or an increase in cell number, which can be 10 or more cell layers thick.  
Row B represents beta-galactosidase staining of frozen bladder sections on the 3 different genotypes of 
mice. Senescent positive cells are stained blue in the nucleus, which is seen in the epithelium of the bladder. The 
stains were evaluated based on their proliferation in the epithelium (see figure 11). There is a significant correlation 
between the Ras and double transgenic mice as compared to the WT.  
Row C represents immunohistochemical staining for p15 in the epithelium of the bladder, seen with the 
formation of a brown color. While it appears the transgenic mice have greater p15 staining, ultimately the 
assessment of these slides falls on the intensity of the p15 stains (darker brown color). The transgenic mice are 
hyperplastic and have p15 staining throughout the epithelium, but the intensity of the staining closely matches 
what was seen in the WT mouse.  
 
A 
B 
C 
WT Mouse 
6 months old 
 
UPII-H-Ras Mouse 
6 months old 
 
UPII-Cre; UPII-H-
Ras; Rbf/f 
6 months old 
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A 
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 Beta-Galactosidase  
 + ++ +++ 
Double Transgenic 0/5 4/5 1/5 
Ras 0/6 5/6 1/6 
WT 5/5 0/5 0/5 
    
 p15   
 + ++ +++ 
Double Transgenic 1/5 3/5 1/5 
Ras 2/6 2/6 2/6 
WT 3/5 1/5 1/5 
Figure 11 
Chart A - Double transgenic refers to the mice with the ultimate genotype of UPII-Cre; Rb
f/f
; UPII-H-Ras, 
while Ras refers to a genotype of UPII-H-Ras, and WT refers to a normal (non-mutated) mouse. All beta-
galactosidase slides were viewed under 10x magnification and significant progression towards senescence was 
defined as more than 20% of the slide’s epithelial layer staining blue (occurring in the nucleus of the epithelial 
cells). All of the slides were rated using + to indicate 0-20% epithelial staining (normal), ++ to indicate 20-60% 
epithelial staining (significant senescent activity), and +++ to indicate 60-100% epithelial staining (substantial 
senescent activity). The results indicate the amount of mice out of the total that were found to have that correlating 
amount of senescence activity out of the total amount of that genotype of mice. In the chart, the yellow shading 
indicates those slides with significant senescence activity Notice here the similarities between the double 
transgenic and Ras mice.  
Chart B – All p15 slides were viewed under 10x magnification and were rated based on brown color 
intensity in the epithelial cytoplasm from + being the least intense to +++ being the most intense.  
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